Kiryat Hadassah Medical Center
P.O. Box 12000
19 articles with KAHR Medical
KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, announced the first closing of an investment round raising $46.5 million.
Samsung Biologics and KAHR Medical Announce Development and Manufacturing Agreement for Cancer Immunotherapy Drug Candidate
Samsung Biologics, the world's leading contract development and manufacturing organization, signed a strategic partnership with KAHR Medical Ltd., a cancer immunotherapy company developing novel multifunctional immune-recruitment proteins.
KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR's Lead Anti-CD47 Candidate in Blood Cancers
KAHR and Cancer Focus Fund, LP, a unique venture capital fund established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and clinical expertise to advance promising cancer therapies, announced that Cancer Focus Fund is investing $5 million to finance a clinical trial of KAHR's lead anti-CD47 candidate, DSP107, in blood cancers.
KAHR Announces Exclusive Licensing Agreement with Thomas Jefferson University for Novel Platform of Bi- and Tri-Specific Fusion Proteins for Cancer Immunotherapy
KAHR adds two preclinical products, DSP502, a TIGITxPD1 fusion protein, and DSP216, a LILRB2xSIRPa fusion protein, to its pipeline
KAHR Announces First Patient Dosed in Phase 1/2 Clinical Trial of DSP107, Bi-Functional CD47x41BB Candidate for the Treatment of Solid Tumors
KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, announced dosing of the first patient in its Phase 1/2 clinical trial assessing its lead product, DSP107, a bi-functional CD47x41BB candidate for the treatment of solid tumors.
Prof. Hagop M. Kantarjian, M.D., Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, has joined KAHR's clinical advisory board.
Data for DSP107, first-in-class bi-functional CD47x41BB targeting compound, to be presented on December 5, 2020
KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, announced that Aron Knickerbocker has been appointed Director and that Bryan Jennings has been appointed Chief Financial Officer of KAHR.
KAHR Medical Announces FDA Clearance of IND Application for DSP107, anti-CD47 Candidate for the Treatment of Solid Tumors
Phase I/II study in patients with solid tumors expected to commence in Q3 2020 at leading sites in the United States
Funds will be used for advancing the Company's next generation immuno-oncology drug candidates, including lead anti-CD47 product for the treatment of solid tumors through Phase I/II study in addition to advancing preclinical pipeline
KAHR Medical Announces Clinical Trial Collaboration to Evaluate DSP107 in Combination With a PD-L1 Checkpoint Inhibitor in Advanced Lung Cancer Patients
KAHR Medical announced a new clinical collaboration with Roche.
Hadasit Bio-Holdings Ltd. Portfolio Companies - ProtAb Ltd. and KAHR Medical to Receive NIS 10.7 Million (Over $2.8 Million USD) in Additional Government Grants
KAHR Medical And Cobra BioManufacturing Partner to Develop Trans Signal Converter Protein Production
KAHR Medical Raises $500K From Hadasit Bio Holdings and the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor of Israel